Kintara Therapeutics, Inc. (KTRA) has seen decrease of 1.13% in the premarket despite any news reported by the company. However, the last trading session closed at $0.354 with a decrease of 10.27%.
Multiyear Research Grant – What’s up?
KTRA announced on 12th January 2022 that Doctor Anna Golebiewska has been awarded with a multiyear research grant. This research grant is awarded by Luxembourg National Research Fund (FNR) and the Cancer Foundation Luxembourg. In Luxembourg, the FNR is the primary source of funding for research. Moreover, the Cancer Foundation Luxembourg is committed to patient assistance and oncology research by educating cancer patients.
Now what?
The acknowledgement and economic assistance from this prestigious organisation for VAL-083 research in Dr. Golebiewska’s laboratory is extremely exciting because it will offer critical data for optimising the clinical use of this first-in-class specific molecular chemotherapeutic. Furthermore, the findings of this study will aid in elucidating possible therapeutic targets for novel co – treatment regimens involving VAL-083, as well as promote the chance to improve therapeutic accuracy in GBM patients.
First International Site Activation by KTRA – More About it
On 30th November 2021, KTRA reported about the site activation in GCAR Phase 2/3 Clinical Trial. The speed with which the treatment arm will be implemented in the research continues to excite the Kintara team. Not only this but the company is thrilled to witness GCAR’s outstanding clinical testing consequences, which drew the team to participate in this exciting and highly efficient registrational study. With 31 sites already operational, including the first international site, the company is hopeful to observe GCAR’s extraordinary clinical trial execution capabilities.
Through response adaptive randomization and a seamless Phase 2/3 design, GBM AGILE is a multinational, novel platform study that aims to find and confirm beneficial medicines for patients with GBM more quickly. The trial will be run under a master protocol that allows numerous medicines. Data from GBM AGILE might be utilized as the basis for new drug applicants and biologics licence applications. This has only been possible because of its novel design and efficient operational infrastructure.
